SEHK:9995Biotechs
RemeGen (SEHK:9995) Stock Could Be 39% Below Fair Value After Telitacicept Approvals
RemeGen (SEHK:9995) is back in focus after China’s National Medical Products Administration approved new indications for its autoimmune drug Telitacicept in Sjögren’s disease and conditionally in IgA nephropathy, expanding its treated patient pools.
See our latest analysis for RemeGen.
At a latest share price of HK$68.5, RemeGen’s 1 day share price return of 1.63% follows a 30 day share price decline of 19.32%. Its 1 year total shareholder return of 37.27% and 3 year total shareholder return...